The purpose of the present invention is to provide a prophylactic or therapeutic agent for cancer pain. The present invention provides a pharmaceutical composition for preventing or treating cancer pain, the composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. [In the formula, m is an integer of 1-4; and R1 is independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group optionally substituted with 1-3 halogen atoms, a methoxy group optionally substituted with 1-3 halogen atoms, and a methylthio group optionally substituted with 1-3 halogen atoms.]
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Provided is a dexmedetomidine-containing non-aqueous external preparation being capable of suppressing the precipitation of a crystal of dexmedetomidine in the preparation, and having satisfactory transdermal absorbability. The non-aqueous external preparation includes: (A) dexmedetomidine or a salt thereof; (B) an aliphatic alcohol having 10 to 12 carbon atoms; (C) a propylene glycol monoester of a fatty acid having 6 to 16 carbon atoms; (D) an organic acid; and (E) an organic acid salt.
A cytotoxicity suppressant by phosaprepitant injection dilute solution having as an active ingredient glucose in an amount effective for isotonization.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61P 1/08 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des nausées, du mal des transports ou des vertigesAntiémétiques
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
4.
AQUEOUS SOLUTION AGENT FOR FOSAPREPITANT INJECTION
Provided is an aqueous solution agent for a fosaprepitant injection, the aqueous solution containing a fosaprepitant and a diethylenetriamine pentaacetic acid.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61P 1/08 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des nausées, du mal des transports ou des vertigesAntiémétiques
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
5.
JELLY PREPARATION CONTAINING LEVOCARNITINE AT HIGH CONCENTRATION
[Problem] The present invention addresses the problem of providing a jelly preparation containing levocarnitine at a high concentration. The present invention also addresses the problem of providing a levocarnitine-rich jelly preparation for use in drugs, (1) which is reduced in adverse side effects on a patient who is subjected to the restriction of the intake of water or an energy (more specifically, the restriction of the intake of a nutrient such as a protein, water, an energy (calorie), common salt, and a mineral including potassium and phosphorus), i.e., a patient who should take account of the "Dietary Recommendations" edited by Japanese Society of Nephrology such as a patient affected by a renal disease, in order to allow the patient to ingest levocarnitine efficiently and safely, (2) which is easy to ingest, and/or (3) which has excellent physical properties and storage stability. [Solution] The problem can be solved by a jelly preparation containing levocarnitine at a high concentration, the jelly preparation having a specified composition.
To provide a nonaqueous external preparation comprising dexmedetomidine in which the crystallization of dexmedetomidine in the preparation is suppressed and which has excellent percutaneous absorbability. A nonaqueous external preparation that comprises: (A) dexmedetomidine or a salt thereof; (B) an aliphatic alcohol having 10-12 carbon atoms; (C) a propylene glycol mono-ester of a fatty acid having 6-16 carbon atoms; (D) an organic acid; and (E) an organic acid salt.
The present invention addresses the problem of providing an oral pharmaceutical composition that (1) has reduced bitterness of levetiracetam of which a single dose is a large amount, (2) provides good ingestion feeling, and/or (3) has a favorable elutability. The present invention provides a gel oral pharmaceutical composition containing levetiracetam, which is an active ingredient, a gelling agent, a sweetening agent, and a pH adjusting agent and having a pH of about 6-7.
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
C07D 207/27 - Pyrrolidones-2 avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux autres atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés directement à l'atome d'azote du cycle
8.
ACIDIC EMULSION COMPOSITION CONTAINING LOCAL ANESTHETIC AGENT
The purpose of the present invention is to provide a local anesthetic agent-containing composition that is (1) fast-acting after administration without being made to be sustained release and that has a lasting drug efficacy, and/or that has (2) good storage stability. Provided is an acidic emulsion composition containing a local anesthetic agent and a glyceride in which a fatty acid having 6 to 12 carbon atoms is ester bonded to a glycerin.
The present invention provides a rocuronium preparation with an excellent stability. The rocuronium preparation contains rocuronium and a buffer solution and having an adjusted pH of 3.5 or less (for example, 2.5 to 3.5). The buffer solution may be a citric acid-sodium hydroxide buffer solution, a tartaric acid-sodium hydroxide buffer solution, a potassium hydrogen phthalate-hydrochloric acid buffer solution, a glycine-hydrochloric acid buffer solution, or the like. Such a rocuronium preparation has, for example, after 6-month storage at 40° C., a generation rate of rocuronium-related substance C of 5% or less.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
Provided is a patch providing sufficiently high absorbability of dexmedetomidine and less skin irritation.
Hydrous adhesive patch comprising dexmedetomidine or a salt thereof and a water-soluble polymer.
Rocuronium preparation causing less pain, method for producing the same, and method for reducing and/or alleviating vascular pain to be induced using the same
Provided is a rocuronium preparation designed to reduce vascular pain to be induced. The rocuronium preparation contains rocuronium and a buffer solution, and has titratable acidity of 100 mEg or less. The buffer solution may be an acetate buffer solution, a citrate buffer solution, a formate buffer solution, a tartrate buffer solution, a phosphate buffer solution, a glycine-hydrochloric acid buffer solution, or a citric acid-phosphate buffer solution.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
Provided are: a method for industrially advantageously producing a high-purity pentapeptide; and a production intermediate thereof. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents an alkyl group or an aralkyl group.)
The present invention provides a rocuronium formulation having excellent stability. This formulation includes rocuronium and a buffer solution, and has a pH adjusted to 3.5 or less (for example, 2.5-3.5). The buffer solution may be a citric acid/sodium hydroxide buffer solution, a tartaric acid/sodium hydroxide buffer solution, a potassium hydrogen phthalate/hydrochloric acid buffer solution, a glycine/hydrochloric acid buffer solution or the like. This type of rocuronium formulation has a rocuronium analog C generation rate of 5% or less after being stored for six months at 40 °C, for example.
The present invention provides an emulsion composition of excellent physical stability over time and suitable safety, which is usable in concentration-increase applications, and characterized by the inclusion of sevoflurane, a fatty acid glyceride, and a hydroxyethyl starch.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
Provided is an adhesive patch that exhibits sufficiently high dexmedetomidine absorbency and little dermal irritation. The water-containing adhesive patch contains a water soluble polymer and dexmedetomidine or a salt thereof.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
16.
ROCURONIUM PREPARATION WITH IMPROVED VASCULAR PAIN, METHOD FOR PRODUCING SAME, AND METHOD FOR SUPPRESSING AND RELIEVING VASCULAR PAIN USING SAME
Provided is a rocuronium preparation that makes it possible to suppress vascular pain. This rocuronium preparation is characterized by containing rocuronium and a buffer and having titratable acidity of 100 mEq or less. The buffer may be an acetate buffer, citrate buffer, formate buffer, tartrate buffer, phosphate buffer, glycine-hydrochloric acid buffer, citrate-phosphate buffer, or the like.
A61K 31/568 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61P 21/02 - Relaxants musculaires, p. ex. pour la tétanie ou les crampes
The hand hygiene moment measuring system of the present invention includes a subject sensing device (2) to sense a subject's position and posture, a movement sensing device (3) to sense a subject's movement, a storage unit (4) to store particular combinations corresponding to hand hygiene opportunities, and a counter (5) to count a number of times combinations of a sensing information of the subject sensing device, a sensing information of the movement sensing device, and an object position information indicating a position of an object, achieved the combinations stored in the storage unit.
The purpose of the present invention is to provide an aripiprazole oral pharmaceutical preparation which has limited acidity and bitterness, poses little burden to the patient when administered, and is highly elutable, and for which the patient himself can readily confirm administration. The present invention pertains to an oral pharmaceutical preparation characterized by containing aripiprazole and a gelling agent, the pH being 4.6 or higher.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
The purpose of the present invention is to provide a general anesthetic medicine which can prevent and/or alleviate an anesthetic-induced neuropathy in the brain (preferably the developing brain). The present invention relates to a medicine which can prevent and/or alleviate an anesthetic-induced neuropathy in the brain (preferably the developing brain), said medicine comprising a combination of a general anesthetic drug and hydrogen.
A61K 31/08 - Éthers ou acétals acycliques, p. ex. paraformaldéhyde
A61K 31/5517 - 1,4-Benzodiazépines, p. ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p. ex. imidazobenzodiazépines, triazolam
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
Provided is a stabilizer of acetaminophen in an aqueous composition, containing glycine. The stabilizer is more effective by further containing at least one kind of sulfites that is selected from the group consisting of sodium sulfite, potassium sulfite, and potassium pyrosulfite. The stabilization includes prevention of precipitation.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
Disclosed are an external preparation for skin for improving wrinkles and sagging, an external preparation for skin for moisture retention, an external preparation for skin for promoting wound healing and an external preparation for lips, each of which contains raspberry ketone or a pharmaceutically acceptable salt thereof as an active ingredient.
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 17/16 - Émollients ou protecteurs, p. ex. contre les radiations
A61Q 19/00 - Préparations pour les soins de la peau
A61Q 19/08 - Préparations contre le vieillissement
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61Q 1/04 - Préparations contenant des colorants cutanés, p. ex. pigments pour les lèvres
A disinfectant which contains the following ingredients (a), (b), (c) and (d) and is free from other bactericidal disinfectants for sterilization: (a) 40 to 90% (w/w) of ethanol, isopropyl alcohol or a mixture of both based on the whole disinfectant, (b) 0.1 to 2% (w/w) of lactic acid based on the whole disinfectant, (c) 0.01 to 2% (w/w) of citric acid based on the whole disinfectant, and (d) 0.001 to 0.1% (w/w) of a zinc compound capable of releasing zinc ions in a solution based on the whole disinfectant.
A01N 37/36 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant au moins un groupe carboxylique ou un thio-analogue, ou d'un de leurs dérivés, et un atome d'oxygène ou de soufre lié par une liaison simple, liés au même squelette carboné, cet atome d'oxygène ou de soufre ne faisant pas partie d'un groupe carboxylique ou d'un thio-analogue, ou d'une de leurs dérivés, p. ex. acides hydroxycarboxyliques
A61L 2/18 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques des substances liquides
Disclosed is a sterilizing/disinfecting composition characterized by containing the following components (a), (b) and (c). (a) at least one alcohol selected from the group consisting of ethanol and isopropanol (b) at least one carboxyvinyl polymer selected from the group consisting of polyacrylic acids, polyacrylic acid salts, copolymers of polyacrylic acids and polyacrylic acid alkyl esters and copolymers of polyacrylic acid salts and polyacrylic acid alkyl esters (c) agar
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
It is intended to provide an external preparation for skin which improves coarsening of skin texture, wrinkles and sagging skin. The external preparation for skin of the invention is characterized by containing nonylic acid vanillylamide at 0.0001% by mass or more and 0.05% by mass or less based on the total of external preparation for skin as an active ingredient and is useful for improving coarsening of skin texture, wrinkles and sagging skin.
Disclosed is a bactericidal disinfectant ointment containing 0.1-4% by mass of at least one substance selected from the group consisting of chlorhexidine and salts thereof and 8-25% by mass of a hydrocarbon alcohol having 2-3 carbon atoms. The bactericidal effect of this disinfectant ointment approved by hand disinfection test continues at least 6 hours.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
(i) A gel composition for sterilization containing 0.2-0.55 w/v% of at least one substance selected from the group consisting of chlorhexidine and salts thereof, 50-99 v/v% of a hydrocarbon alcohol having 2-3 carbon atoms, a thickening agent and a wetting agent, while having a viscosity of 10-1000 mPs. (ii) A gel composition for sterilization containing 0.2-0.55 w/v% of at least one substance selected from the group consisting of chlorhexidine and salts thereof, 50-99 v/v% of a hydrocarbon alcohol having 2-3 carbon atoms, 0.05-10 w/v% of a thickening agent and 0.15-10 w/v% of a wetting agent.
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
brevets
